Technical Debt Stifling Path to AI Adoption for Global Enterprises, Says Research
The study found that two in three (68%) respondents say legacy systems and applications are preventing their organization from fully embracing more modern technologies. An overwhelming majority (88%) are also concerned about how their technical debt impacts their ability to keep pace with more agile, innovative competitors – with one in three (29%) indicating either 'clear' or 'significant' concern. More than half (57%) even acknowledge their reliance on legacy systems 'likely' or 'highly likely' causes customers to defect due to the resulting poor experiences.
Other findings from the research include:
Legacy dependency: Almost half (48%) say they can't stop supporting their legacy applications – despite wanting to – because the systems are still business critical. Almost half (47%) say their oldest legacy application is between 11-20 years old, while more than one in ten (16%) run apps between 21-30 years old.
Legacy Ineffectiveness: Two thirds (68%) of respondents say legacy systems are preventing their organization from operating as effectively as possible, citing time spent on maintenance (44%), the siloed nature of disconnected systems, and the cost of maintenance (both 37%) as the leading contributing factors. Just 7% feel legacy applications caused no problems for their business whatsoever.
The customer does not always come first: Three quarters (74%) of respondents agree their business prioritizes investments that improve profitability instead of ways to improve customer experience, such as technologies to help modernize legacy applications. This echoes research conducted by Pega earlier this year among consumers, 69% of whom felt businesses were prioritizing profits over positive customer experiences in their IT investments. It could also help explain why one in three (32%) say the average resolution time to customer queries has increased between 26-50% in the last 12 months – a direct result of staff running multiple or outdated legacy applications.
Quotes & Commentary
'This study highlights how easy it can be for enterprises to get dragged down by outdated systems that are unwieldy to use and resource-intensive to maintain – perpetuating an organizational culture of waste,' said Don Schuerman, chief technology officer, Pega. 'While the bottom-line cost to businesses is significant, the real cost of technical debt is its impact on the experiences that today's customers both demand and deserve. It's time for businesses to change their mindset, harness the power of generative AI through innovations like Pega Blueprint™, to enact fast, efficient legacy transformation, and free themselves from the vicious cycle of technical debt…before they lose their customers for good.'
Notes
Pega surveyed more than 500 IT decision makers worldwide on their legacy transformation projects, how they work, and the challenges and opportunities they present. The results included responses from North America, the United Kingdom, France, Australia, and Germany.
Methodology
For all respondents, Pega defined 'technical debt' and 'legacy systems' as outdated hardware, software, or technology platforms that remain in use due to their critical role in business operations. This is despite challenges such as limited scalability, security vulnerabilities, high maintenance costs, and incompatibility with modern technologies. Technical debt is the implied, often intangible, cost of additional work, or strain using them places upon the business.
Additional Resources
About Pegasystems
Pega is The Enterprise Transformation Company that helps organizations Build for Change® with enterprise AI decisioning and workflow automation. Many of the world's most influential businesses rely on our platform to solve their most pressing challenges, from personalizing engagement to automating service to streamlining operations. Since 1983, we've built our scalable and flexible architecture to help enterprises meet today's customer demands while continuously transforming for tomorrow. For more information on Pega (NASDAQ: PEGA), visit www.pega.com
All trademarks are the property of their respective owners.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 minutes ago
- Business Wire
Quanterix Announces Cooperation Agreement with Kent Lake Capital
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has entered into a cooperation agreement (the 'Agreement') with Kent Lake Partners LP (together with its affiliates, 'Kent Lake'). The Company has committed to appointing a new independent director by December 1, 2025. The new director will be identified through a comprehensive search process in which both Kent Lake and the Board of Directors (the 'Board') shall have meaningful participation. In addition, the Company will seek approval at the 2025 Annual Meeting of Stockholders (the 'Annual Meeting') to declassify its Board and will amend its bylaws to adopt a majority voting standard for uncontested director elections. Under the terms of the Agreement, Kent Lake has agreed to withdraw its director nominations and shareholder proposals previously submitted in connection with the Annual Meeting and will support the Board's candidates. In addition, Kent Lake has agreed to customary standstill and voting commitments until thirty days prior to the nomination deadline for Quanterix's 2027 Annual Meeting. 'We are pleased to have reached a constructive agreement with Kent Lake that will allow the Board and management team to remain fully focused on executing the Company's strategy, navigating the dynamic industry environment and maximizing the benefits of the Akoya transaction,' said William P. Donnelly, Chairman of the Quanterix Board. 'We look forward to working with Kent Lake to identify a new director who can help us unlock the Company's full potential and advance our goal of changing the way disease is detected, understood and treated.' Benjamin Natter, Managing Member of Kent Lake, said, 'We are confident that the addition of a new independent director and governance enhancements will benefit the Company and its stockholders and help position Quanterix for continued success.' The full cooperation agreement between Quanterix and Kent Lake will be filed with the U.S. Securities and Exchange Commission on a Current Report on Form 8-K. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at Additional Information and Where to Find It The Company intends to file a definitive proxy statement on Schedule 14A, an accompanying WHITE proxy card and other relevant documents with the SEC in connection with the solicitation of proxies from the Company's stockholders for the Company's Annual Meeting. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE COMPANY'S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the definitive proxy statement, an accompanying WHITE proxy card, any amendments or supplements to the definitive proxy statement and other documents filed by the Company with the SEC at no charge at the SEC's website at Copies will also be available at no charge on the Company's investor relations website at or by contacting the Company's Investor Relations department at as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC. Participants in the Solicitation The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from the Company's shareholders in connection with matters to be considered at the Annual Meeting. Information regarding the direct and indirect interests, by security holdings or otherwise, of the Company's directors and executive officers is included in the sections entitled 'Security Ownership of Certain Beneficial Owners and Management,' 'Management and Corporate Governance' and 'Executive Officer and Director Compensation' of the Company's Proxy Statement on Schedule 14A for its 2024 annual meeting of shareholders, filed with the SEC on April 15, 2024 (available here); in the sections entitled 'Directors, Executive Officers and Corporate Governance,' 'Executive Compensation—Executive Officer and Director Compensation Tables' and 'Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters—Security Ownership of Certain Beneficial Owners and Management' of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 17, 2025 (available here) (as amended on April 30, 2025 (available here)), and in the Company's Current Report on Form 8-K filed with the SEC on July 8, 2025 (available here). Changes to the direct or indirect interests of the Company's directors and executive officers are set forth in Initial Statements of Beneficial Ownership filed with the SEC on May 2, 2025, May 19, 2025, June 3, 2025, June 10, 2025, June 17, 2025, July 7, 2025, July 17 for Mr. Masoud (available here, here, here, here, here, here and here); on May 19, 2025, June 17, 2025 and July 17, 2025 for Ms. Vandana (available here, here and here); on June 9, 2025 and July 2, 2025 for Mr. Donnelly (available here and here); on June 9, 2025, June 13, 2025 and July 2, 2025 for Mr. Walt (available here, here and here); on July 2, 2025 for Mr. Meister (available here); on July 9, 2025 and July 10, 2025 for Mr. Mendel (available here and here); and on July 9, 2025 and July 10, 2025 for Ms. Lai-Goldman (available here and here). These documents are available free of charge as described above. Updated information regarding the identities of potential participants and their direct or indirect interests, by security holdings or otherwise, in the Company will be set forth in the definitive proxy statement for the Annual Meeting and other relevant documents to be filed with the SEC, if and when they become available. Cautionary Statement Regarding Forward-Looking Statements Statements included in this press release which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix's future business outlook, operations, strategy and financial performance. Words and phrases such as 'may,' 'approximately,' 'continue,' 'should,' 'expects,' 'projects,' 'anticipates,' 'is likely,' 'look ahead,' 'look forward,' 'believes,' 'will,' 'intends,' 'estimates,' 'strategy,' 'plan,' 'could,' 'potential,' 'possible' and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix's future business, operations, strategy and financial performance: risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs; risks that we may not realize the expected benefits of our cost reduction actions; risks associated with the anticipated timing for launch of, and features of, Quanterix's next-generation instrument, Simoa ONE; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc.; that Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to the restatement of Quanterix's consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation; risks related to Quanterix's ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation; Quanterix's ability to realize the intended benefits of its assay redevelopment program; and Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products. Additional factors that could cause results to differ materially from those described above can be found in the Proxy Statement/Prospectus, and in periodic reports filed by Quanterix and Akoya with the SEC, including the 'Risk Factors' sections contained therein, which are available on the SEC's website at All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix's underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
Business Wire
10 minutes ago
- Business Wire
National Clinical Reimbursement Leader Kelly Roberts Joins CoreCare to Lead AI-Powered Transformation
NEW YORK--(BUSINESS WIRE)-- CoreCare, the leading AI-powered workflow platform for post-acute and long-term care providers, announced today that Kelly Roberts has joined the company as Senior Vice President of MDS Innovation & Transformation. Kelly Roberts brings more than two decades of clinical reimbursement leadership to CoreCare, most recently serving as Senior VP of Clinical Reimbursement at Creative Solutions in Healthcare, the nation's fifth largest skilled nursing operator. Roberts brings more than two decades of clinical reimbursement leadership to CoreCare, most recently serving as Senior Vice President of Clinical Reimbursement at Creative Solutions in Healthcare, the nation's fifth largest skilled nursing operator. There, she oversaw reimbursement across more than 160 facilities, led systemwide MDS strategies, and founded one of the largest MDS leadership summits in the country. At CoreCare, Roberts will lead the development of next-generation AI solutions designed to improve reimbursement accuracy, ensure compliance, and help skilled nursing facilities (SNFs) thrive in an increasingly complex environment. Her appointment comes as CoreCare's revenue has more than doubled year over year, with its platform now powering intake, eligibility, and billing automation. 'Kelly's leadership has always been rooted in collaboration,' said Gary Blake, President and CEO of Creative Solutions in Healthcare. 'She worked hand in hand with our clinical compliance, operations teams, and leaders across every department to strengthen our systems and elevate how we serve. We celebrate her taking this next step, knowing she will bring that same spirit of partnership and innovation to the industry through her work at CoreCare.' 'I'm excited to be a part of the CoreCare team to lead this new era of AI-driven MDS technology and the possibilities it brings to improve accuracy, efficiency, and outcomes. Our goal is simple: support staff where they need it most - streamlining clinical reimbursement so they can focus on resident care,' said Roberts. 'Kelly is one of the most respected minds and leaders in skilled nursing reimbursement,' said Dennis Antonelos, CEO and Co-founder of CoreCare. 'She's lived the challenges operators face and knows what excellence looks like from the inside. With her leadership, we're helping providers transform their operations with AI, capture more accurate reimbursement, and stay financially strong in today's high-stakes environment.' About CoreCare CoreCare is the leading AI-powered workflow platform built specifically for post-acute and long-term care providers. Trusted by thousands of skilled nursing facilities nationwide, CoreCare's platform replaces spreadsheets, manual reviews, and disconnected portals with technology that enables expert-level decisions and teamwork at every step of the revenue cycle. Backed by Y Combinator and leading health tech investors, CoreCare is building the infrastructure for AI-powered healthcare operations. To learn more about CoreCare, visit and connect with us on LinkedIn.
Business Wire
10 minutes ago
- Business Wire
Everspin Appoints Sean Dougherty Vice President of Sales
CHANDLER, Ariz.--(BUSINESS WIRE)--Everspin Technologies, Inc. (NASDAQ: MRAM), the world's leading developer and manufacturer of magnetoresistive random access memory (MRAM), announced today the appointment of Sean Dougherty as Vice President of Sales, effective immediately. Dougherty brings over two decades of experience in the semiconductor industry, spanning engineering, customer enablement, and global sales leadership roles. Most recently, he served as Chief Revenue Officer of Intel's Altera division, where he led global revenue-generating functions including sales, field applications engineering, and business management. Before that, he led Altera's Worldwide Technical Customer Enablement organization, overseeing technical sales and support teams globally. In his role at Everspin, Dougherty will lead the company's sales strategy and growth, provide leadership to its sales and marketing team to secure new business while ensuring customer satisfaction. Earlier in his career, Dougherty held engineering leadership roles in the communications sector, managing teams focused on ASIC, FPGA, and system design for high-volume commercial deployments. He has a Bachelor of Science in Computer Engineering from the Wentworth Institute of Technology in Boston. David Schrenk, who has been the VP of Sales and Business Development for the last three years, will now focus his efforts exclusively on Business Development. Schrenk successfully navigated Everspin to a path of revenue growth while developing strategic partnerships, which has turned into a personal objective and passion for him. "We have reached a point in our journey where both sales execution and strategic partnerships require distinct and dedicated leadership,' said Sanjeev Aggarwal, President and CEO of Everspin. 'This structural change reflects our ambition to accelerate both direct revenue monetization and strategic expansion, allowing us to better serve our customers and unlock new opportunities. Sean brings a combination of engineering depth and customer-first sales leadership, and his track record of building high-performing teams and scaling revenue aligns perfectly with our next phase of growth across new and existing markets." "Everspin's MRAM solutions are solving data persistence and power challenges across industries," said Dougherty. "I'm excited to help expand that reach through deeper technical engagement, strong global partnerships and continued delivery of differentiated memory solutions." About Everspin Technologies Everspin Technologies, Inc. is the world's leading provider of magnetoresistive RAM (MRAM). Everspin MRAM delivers the industry's most robust, highest-performance non-volatile memory for industrial IoT, data centers, and other mission-critical applications where data persistence is paramount. Headquartered in Chandler, Arizona, Everspin provides commercially available MRAM solutions to a large and diverse customer base. For more information, visit NASDAQ: MRAM. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements regarding future results that involve risks and uncertainties that could cause actual results or events to differ materially from the expectations disclosed in the forward-looking statements. Actual results could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including, without limitation, the risks set forth under the caption "Risk Factors" in Everspin's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 27, 2025, and its Quarterly Reports on Form 10-Q filed with the SEC during 2025, as well as in its subsequent filings with the SEC. Any forward-looking statements made by Everspin in this press release speak only as of the date on which they are made, and subsequent events may cause these expectations to change. Everspin disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events, or otherwise, except as required by law.
